Dysport® Info

With these injections, Dr. Graham can prevent future furrows on or around the:        

• Eyebrows     
• Forehead     
• Eyes     
• Mouth     
• Neck    

Contraction of these facial mimetic muscles can create deep wrinkles and furrows and may be misinterpreted by others as anger, aggression, anxiety or just aging. In either case, selective paralysis of these small muscles alleviate this look and gives a more refreshed soft appearance to the face.

• Deep furrows or overly active muscles between the eyebrows 
• Horizontal creases on the forehead 
• Crow's feet in the lateral eye region 
• Platysmal bands or the bands of muscle in front of the neck 
• Muscles around the chin and mouth that cause excessive distortion of the overlaying skin

Administered in a matter of minutes, Dr. Graham can help his patients appear more rested and rejuvenated. 

Dysport® treats moderate to severe frown lines between the eyebrows by reducing specific muscle activity. Wrinkles are caused by repeated movements and muscle contractions, which means they can even develop in younger adults. One injection into each of 5 points between and above the eyebrows temporarily prevents muscle contractions that cause frown lines, leaving the rest of your face to move naturally. In other words, no frozen look, just natural-looking results. You can control your look instead of your look controlling you.

Forget frown lines between the eyebrows for up to 4 months.

You’ve got better things to do than think about what your frown lines look like. In just one 10- to 20-minute treatment, Dysport ® may help improve the look of your frown lines between the eyebrows for up to 4 months.† The majority of patients see improvement in just 2–3 days after treatment. Results of repeat treatments may be comparable to your first use. Another plus? There is minimal downtime after your treatment, which means you can get back to your day faster.

Who should use Dysport®?

Frown lines between your eyebrows got you down? Stand up to those lines with Dysport®. If you’re under 65 and seeking treatment to improve the look of wrinkles between your eyebrows, Dysport® may be for you. But before you begin, read below to help you make the safest, most informed decision. Always speak with Dr. Graham about any concerns you may have and together you can make an informed decision.

Do not take Dysport®  if you:

Are allergic to Dysport® or any of the ingredients in Dysport®. See the end of the Dysport® Medication Guide for a list of ingredients in Dysport® Are allergic to cow's milk protein Had an allergic reaction to any other botulinum toxin product, such as Myobloc® (rimabotulinumtoxinB), Botox® (onabotulinumtoxinA) or Xeomin® (incobotulinumtoxinA) Have a skin infection at the planned injection site.

Dysport® may not be right for you if:

• You have had surgical changes to your face 
• You have very weak muscles in the treatment area 
• Your face looks very different from side to side 
• The injection site is inflamed 
• You have droopy eyelids or sagging eyelid folds 
• You have deep facial scars 
• You have thick, oily skin 
• Your wrinkles can't be smoothed by spreading them apart

References

Data on file. Dysport® Challenge. Fort Worth, TX: Galderma Laboratories, L.P. October 2010. Ipsen. Dysport® Cosmesis Global Indications. May 2012. 

Data on file, Galderma Laboratories, L.P. Medicines and Healthcare products Regulatory Agency (MHRA). Botulinum Toxin Type A Powder For Solution For Injection (Clostridium botulinum toxin type A - Haemagglutinin complex). http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con108644.pdf . Accessed May 11, 2015. 

Data on file. MA-Y-97-52120-085 (GL-2) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. 

Data on file. MA-Y-97-52120-718 (GL-3) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. 

Data on file. MA-Y-97-52120-719 (GL-1) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. Dysport® for Injection Package Insert. Fort Worth, TX: Galderma Laboratories, L.P.; July 2016.